GB Sciences Stock Price, News & Analysis
Company Description
GB Sciences (OTC Link: GBLX) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $81.4K.
GBLX stock has declined 40.0% over the past year. Shares last traded at $0.0003.
On a trailing twelve-month basis, GB Sciences reported revenue of $0 with net income of -$1.4M.
This page provides a comprehensive overview of GBLX stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
GB Sciences (GBLX) stock last traded at $0.0003. Over the past 12 months, the stock has lost 40.0%. At a market capitalization of $81.4K, GBLX is classified as a micro-cap stock with approximately 407.1M shares outstanding.
Latest News
GB Sciences has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 4 with negative movement. Key topics include AI. View all GBLX news →
SEC Filings
Financial Highlights
GB Sciences generated $0 in revenue over the trailing twelve months, operating income reached -$1.4M, and net income was -$1.4M. The company generated -$976K in operating cash flow. With a current ratio of 0.02, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Days to Cover History
GBLX Company Profile & Sector Positioning
GB Sciences (GBLX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing GBLX often look at related companies in the same sector, including Adhera Therapeutics Inc (ATRX), U S Stem Cell Inc (USRM), Reneuron Group (RNUGF), Tracon Pharmaceu (TCON), and Syros Pharmaceut (SYRS). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate GBLX's relative position within its industry.